Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "Pharma"

3866 News Found

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
News | August 14, 2022

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.


Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors
Drug Approval | August 13, 2022

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

Company creates Younger T Cells for fighting cancer using its NR2F6 technology


IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr
News | August 12, 2022

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal


Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr
News | August 12, 2022

Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr

The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.


Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr
News | August 11, 2022

Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr

The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.


Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director
People | August 10, 2022

Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director

He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years


Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
News | August 10, 2022

Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr

The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.


JB Pharma records revenue growth of 30% in Q1 FY23
News | August 09, 2022

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23


Valiant Organics to start production of OAP and Pharma Intermediates
News | August 08, 2022

Valiant Organics to start production of OAP and Pharma Intermediates

Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23